FDA approves Teva Pharmaceuticals' first GLP-1 obesity drug
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
The new facility will provide an important boost to vaccine capacity in Africa
The initiative aims to connect startups and tech companies with its business units,
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Subscribe To Our Newsletter & Stay Updated